title: HDL and endothelial protection.
abstract: High-density lipoproteins (HDLs) represent a family of particles characterized by the presence of apolipoprotein A-I (apoA-I) and by their ability to transport cholesterol from peripheral tissues back to the liver. In addition to this function, HDLs display pleiotropic effects including antioxidant, anti-apoptotic, anti-inflammatory, anti-thrombotic or anti-proteolytic properties that account for their protective action on endothelial cells. Vasodilatation via production of nitric oxide is also a hallmark of HDL action on endothelial cells. Endothelial cells express receptors for apoA-I and HDLs that mediate intracellular signalling and potentially participate in the internalization of these particles. In this review, we will detail the different effects of HDLs on the endothelium in normal and pathological conditions with a particular focus on the potential use of HDL therapy to restore endothelial function and integrity.
authors.affiliation: INSERM UMR698, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Tran-Dinh
authors.forename: D
authors.initials: D
authors.lastname: Diallo
authors.forename: S
authors.initials: S
authors.lastname: Delbosc
authors.forename: L Maria
authors.initials: LM
authors.lastname: Varela-Perez
authors.forename: Q B
authors.initials: QB
authors.lastname: Dang
authors.forename: B
authors.initials: B
authors.lastname: Lapergue
authors.forename: E
authors.initials: E
authors.lastname: Burillo
authors.forename: J B
authors.initials: JB
authors.lastname: Michel
authors.forename: A
authors.initials: A
authors.lastname: Levoye
authors.forename: J L
authors.initials: JL
authors.lastname: Martin-Ventura
authors.forename: O
authors.initials: O
authors.lastname: Meilhac
mesh_terms: D000818:Animals; D017209:Apoptosis; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D008246:Lysophospholipids; D008954:Models, Biological; D018110:Receptors, Lipoprotein / Q000378:metabolism*; D013110:Sphingosine / Q000031:analogs & derivatives; D014657:Vasculitis / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy
chemical_list: D008075:Lipoproteins, HDL; D008246:Lysophospholipids; D018110:Receptors, Lipoprotein; C031616:high density lipoprotein receptors; C060506:sphingosine 1-phosphate; D013110:Sphingosine